Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTA18 lopinavir/ritonavir tablet dosing study in children with HIV-1
ISRCTN02452400Phase 3Completed
- Sponsor
- Penta Foundation
- Start
- Sep 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Penta Foundation. Primary endpoints: Confirmed virologic rebound at or above 400 copies/mL, Pharmacokinetics after twice-daily dosing versus historical data and 1 more. Started Sep 2009; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ISRCTN02452400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN02452400.